(Stock Code: 8156)
2022/2023
Interim Report
CHARACTERISTICS OF GEM ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")
GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.
Given the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.
Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.
This report, for which the directors (the "Directors") of Sinopharm Tech Holdings Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.
SINOPHARM TECH HOLDINGS LIMITED INTERIM REPORT 2022/2023 | 1 |
INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2022
RESULTS
The board of Directors of the Company (the "Board") announces that the unaudited condensed consolidated interim results of the Company and its subsidiaries (collectively the "Group") for the three months and six months ended 31 December 2022 (the "Period 2022"), together with the selected comparative unaudited figures for the corresponding period in 2021 (the "Period 2021"), are as follows:
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the three months and six months ended 31 December 2022
(Unaudited) | (Unaudited) | ||||||||||
Three months ended | Six months ended | ||||||||||
31 December | 31 December | ||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||
Notes | HK$'000 | HK$'000 | HK$'000 | HK$'000 | |||||||
Revenue | 3 | 9,398 | 10,051 | 15,025 | 11,730 | ||||||
Costs of sales and services | (7,859) | (7,820) | (11,986) | (9,137) | |||||||
Gross profit | 1,539 | 2,231 | 3,039 | 2,593 | |||||||
Other income and gains/(losses) | 4 | 17,324 | 6,495 | 28,003 | 15,265 | ||||||
Selling and distribution expenses | (1,219) | (456) | (1,301) | (620) | |||||||
Administrative and operating expenses | (4,182) | (11,019) | (9,439) | (24,791) | |||||||
Share of (loss)/profits of associates | - | 3,185 | (531) | 3,247 | |||||||
Operating profit/(loss) | 13,462 | 436 | 19,771 | (4,306) | |||||||
Finance costs | 5 | (2,187) | (4,439) | (4,002) | (9,071) | ||||||
Profit/(Loss) before tax | 6 | 11,275 | (4,003) | 15,769 | (13,377) | ||||||
Income tax expense | 7 | - | - | - | - | ||||||
Profit/(Loss) for the period | 11,275 | (4,003) | 15,769 | (13,377) | |||||||
Profit/(Loss) for the period | |||||||||||
attributable to: | |||||||||||
Equity holders of the Company | 11,026 | (4,108) | 15,408 | (13,503) | |||||||
Non-controlling interests | 249 | 105 | 361 | 126 | |||||||
11,275 | (4,003) | 15,769 | (13,377) | ||||
2 | SINOPHARM TECH HOLDINGS LIMITED INTERIM REPORT 2022/2023 |
INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2022
(Unaudited) | (Unaudited) | ||||||||||
Three months ended | Six months ended | ||||||||||
31 December | 31 December | ||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||
Notes | HK$'000 | HK$'000 | HK$'000 | HK$'000 | |||||||
Other comprehensive (expenses)/ | |||||||||||
income for the period, net of tax: | |||||||||||
Items that may be reclassified | |||||||||||
subsequently to profit or loss: | |||||||||||
Exchange differences arising on | |||||||||||
translation of financial statements of | |||||||||||
overseas operations | (1,718) | 281 | (2,227) | 43 | |||||||
Total comprehensive income/ | |||||||||||
(expenses) for the period | 9,557 | (3,722) | 13,542 | (13,334) | |||||||
Total comprehensive income/ | |||||||||||
(expenses) for the period | |||||||||||
attributable to: | |||||||||||
Equity holders of the Company | 9,075 | (3,974) | 13,692 | (13,607) | |||||||
Non-controlling interests | 482 | 252 | (150) | 273 | |||||||
9,557 | (3,722) | 13,542 | (13,334) | ||||||||
Earnings/(Loss) per share attributable | |||||||||||
to equity holders of the Company | 8 | ||||||||||
Basic | HK0.24 cents | (HK0.09 cents) | HK0.34 cents | (HK0.30 cents) | |||||||
Diluted | N/A | N/A | N/A | N/A | |||||||
The accompanying notes on pages 7 to 23 form an integral part of this interim financial report.
SINOPHARM TECH HOLDINGS LIMITED INTERIM REPORT 2022/2023 | 3 |
INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2022
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
At 31 December 2022
(Unaudited) | (Audited) | ||||||
31 December | 30 June | ||||||
2022 | 2022 | ||||||
Notes | HK$'000 | HK$'000 | |||||
Non-current assets | 3,247 | ||||||
Property, plant and equipment | 9 | 3,850 | |||||
Right-of-use assets | 400 | 800 | |||||
Goodwill | - | - | |||||
Interests in joint ventures | - | - | |||||
Interests in associates | - | 23,621 | |||||
Financial assets at fair value through other | 21,704 | - | |||||
comprehensive income | |||||||
Deposits for acquisition of property, plant | 537 | ||||||
and equipment | 537 | ||||||
25,888 | 28,808 | ||||||
Current assets | |||||||
2,472 | |||||||
Inventories | 682 | ||||||
Trade and other receivables and | 18,639 | ||||||
prepayments | 10 | 44,405 | |||||
Bank balances and cash | 7,283 | 2,991 | |||||
28,394 | 48,078 | ||||||
Current liabilities | |||||||
Trade payables, accruals and other | 54,797 | ||||||
payables | 11 | 76,633 | |||||
Amount due to directors | - | 8,490 | |||||
Amounts due to related parties | - | 12,144 | |||||
Amounts due to a shareholder | 105,747 | 105,747 | |||||
Lease liabilities | 644 | 934 | |||||
Convertible bonds | 12 | 48,190 | 44,995 | ||||
Deferred tax liabilities | 1,307 | 1,307 | |||||
Tax liabilities | 33 | 33 | |||||
210,718 | 250,283 | ||||||
Net current liabilities | (182,324) | (202,205) | |||||
Total assets less current liabilities | (156,436) | (173,397) | |||||
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Sinopharm Tech Holdings Ltd. published this content on 13 February 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 February 2023 14:21:01 UTC.